Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 3/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12443460 | 1.00 | CYP3A4 (0.47) | CYP3A4CYP2D6BCHEPARP1KCNK3 | |
| SCHEMBL26287093 | 1.00 | CYP3A4 (0.47) | CYP3A4CYP2D6BCHEPARP1KCNK3 | |
| SCHEMBL18800228 | 0.98 | CYP3A4 (0.46) | CYP3A4CYP2D6BCHEPARP1KCNK3 | |
| SCHEMBL31734262 | 0.98 | CYP3A4 (0.46) | CYP3A4CYP2D6BCHEPARP1KCNK3 | |
| SCHEMBL490080 | 0.94 | CYP3A4 (0.53) | CYP3A4CYP2D6BCHEPARP1MMP3 | |
| SCHEMBL172515 | 0.94 | CYP3A4 (0.53) | CYP3A4CYP2D6BCHEPARP1MMP3 | |
| SCHEMBL9020148 | 0.94 | CYP3A4 (0.53) | CYP3A4CYP2D6BCHEPARP1MMP3 | |
| Hydrochloric Acid SCHEMBL490045 | 0.92 | CYP3A4 (0.51) | CYP3A4CYP2D6BCHEPARP1MMP3 | |
| SCHEMBL29865289 | 0.85 | — | — | |
| SCHEMBL15374826 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11767294-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173017-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| US-20210353777-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-07 | — | — | US | disclosed |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2021-05-27 | — | — | US | disclosed |
| EP-3261443-B1 | DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | UNIV RICE WILLIAM M (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3275861-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170362259-A1 | PROCESS AND INTERMEDIATES FOR MAKING TUBULYSIN ANALOGS | BRISTOL-MYERS SQUIBB COMPANY | 2017-12-21 | — | — | US | disclosed |
| US-9662402-B2 | Drug delivery conjugates containing unnatural amino acids and methods for using | ENDOCYTE, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2017053619-A1 | GLYPICAN-3BINDING FIBRONECTIN BASED SCAFFLOLD MOLECULES | BRISTROL-MYERS SQUIBB COMPANY (US) | 2017-03-30 | — | — | WO | disclosed |
| EP-2956173-B1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2017031209-A1 | TUBULYSIN ANALOGS AND METHODS | ENDOCYTE, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| EP-2010185-B1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2012-06-13 | — | — | EP | disclosed |
| WO-2012019123-A1 | PROCESSES FOR PREPARING TUBULYSINS | ENDOCYTE, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353777-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | CYP3A4 2674/4885CYP2D6 2322/4885BCHE 1261/4885 |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CYP3A4 4580/4885CYP2D6 4311/4885BCHE 1049/4885 |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | CYP3A4 1679/4885CYP2D6 608/4885BCHE 675/4885 |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | CYP3A4 1679/4885CYP2D6 608/4885BCHE 675/4885 |
| US-11767294-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | CYP3A4 4701/4885CYP2D6 3788/4885BCHE 2582/4885 |
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | CYP3A4 4259/4885CYP2D6 3324/4885BCHE 2629/4885 |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | FOLH1, KLK3, CD47 | CYP3A4 4580/4885CYP2D6 4311/4885BCHE 1049/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | CYP3A4 4730/4885CYP2D6 4184/4885BCHE 1237/4885 |
| US-20170362259-A1 | PROCESS AND INTERMEDIATES FOR MAKING TUBULYSIN ANALOGS | NGLY1, TEK, MAN2B2 | CYP3A4 3394/4885CYP2D6 3894/4885BCHE 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.